Cerebellar Control Infusion Study
Objective: Control experiment to verify that AP5 infusion effects on fear extinction are amygdala-specific by infusing AP5 into the interpositus nucleus of the cerebellum as a control site
This is a Cerebellar Control Infusion Study protocol using Not explicitly stated in provided text as the model organism. The procedure involves 4 procedural steps, 2 equipment items, 1 materials. Extracted from a 1992 paper published in Journal of Neuroscience.
Model and subjects
Not explicitly stated in provided text • Not explicitly stated in provided text • Not explicitly stated in provided text • Not explicitly stated in provided text • Not explicitly stated in provided text • Not explicitly stated in provided text
Study window
Estimated timing pending
Core workflow
Prepare AP5 infusion • Infuse AP5 into interpositus nucleus of cerebellum • Conduct fear-potentiated startle testing
Primary readouts
- Extinction of fear-potentiated startle response
- Whether AP5 infusion into cerebellum blocks extinction (expected: no blockade)
- Comparison of extinction between amygdala and cerebellar infusion sites
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Prepare AP5 infusion
Prepare NMDA antagonist AP5 (D,L-2-amino-5-phosphonovaleric acid) for infusion
Note: This is a control infusion site experiment
View evidence from paper
“infusion of the NMDA antagonist D,L-2-amino-5-phosphonovaleric acid (AP5) into the amygdala”
Infuse AP5 into interpositus nucleus of cerebellum
Deliver AP5 infusion into the interpositus nucleus of the cerebellum as a control site to verify amygdala-specific effects
Note: This is the control site infusion; the interpositus nucleus is used as a control brain region
View evidence from paper
“Infusion of AP5 into the interpositus nucleus of the cerebellum, a control site, did not block extinction.”
Conduct fear-potentiated startle testing
Test fear extinction using the fear-potentiated startle paradigm following AP5 infusion into the cerebellum
Note: Measure whether extinction is blocked or proceeds normally
View evidence from paper
“the fear-potentiated startle paradigm was employed to begin to investigate neural mechanisms of extinction.”
Measure extinction outcome
Assess whether AP5 infusion into the interpositus nucleus blocks extinction of conditioned fear
Note: Control experiment to demonstrate blockade of extinction is amygdala-specific
View evidence from paper
“Infusion of AP5 into the interpositus nucleus of the cerebellum, a control site, did not block extinction.”